TY - JOUR T1 - TTF 1- expression and pemetrexed based chemotherapy. A retrospective analysis JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2015.PA4292 VL - 46 IS - suppl 59 SP - PA4292 AU - Claus Steppert AU - Hannah Foerster AU - Rumo Leistner AU - Jens Krugmann Y1 - 2015/09/01 UR - http://erj.ersjournals.com/content/46/suppl_59/PA4292.abstract N2 - In 2013 Garon et al published the results of the translational research of the Pointbreak study showing a significant different overall survival (OS) in TTF1- positive adenocarcinomas treated by pemetrexed compared to TTF 1 negative tumors.The aim of this study was to prove whether this finding can be reproduced in not selected real life patients.57 patients (pts), 26m, 31f, aged 42 to 78, median 64 years with bronchogenic adenocarcinoma undergoing pemetrexed based chemotherapy were analyzed for TTF 1 expression and outcome. 46 (80%) were TTF 1 positive, 11 (20%) TTF 1 negative. There was no statistical difference in age, gender, EGFR mutation status and proportion undergoing maintenance therapy in both groups.Response was different with 48% vs 27% partial remission, 48% vs. 36% stable disease and 4% vs 36% progressive disease in favor of TTF 1 expression (Χ2=9,775, p<0.006). There was superior overall survival (MST 18.3 vs. 7.6 months, p=0.0055) and a trend towards superior progression free survival (MST 6.9 vs 4 months, p=0.08) for TTF 1 positive patients. One and two year survival was 64% and 31% for TTF 1 pos. vs. 27% 1 year with no 2 year survival for TTF 1 neg.Our results perfectly confirm the data presented by Garon et. al. with only one third of the pts. receiving pemetrexed maintenance in our study. ER -